Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
LONDON Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 scientists hunting for new ways to treat type 2 diabetes.
The decision is likely to be welcomed by Prime Minister Theresa May, who last week highlighted life sciences when she laid out a new industrial strategy designed to rebalance Britain’s heavily services-based economy after it leaves the EU.
Oxford medicine professor John Bell said the new set-up, which will allow for daily interactions between academic and industrial scientists, underlined the importance of sharing research and cutting-edge science across boundaries.
Britain’s vote to leave the European Union has raised concerns in the life sciences sector, with academics fretting over a potential gap in funding currently provided by the EU and drugmakers concerned over future medicine regulation.
The European Medicines Agency – based in London for now, but likely to move after Brexit – currently offers a one-stop-shop for drug approvals, smoothing the sale of pharmaceuticals across borders.
Given these challenges, some drug company executives have warned that Britain could lose its appeal as a center for research and manufacturing. However, Britain’s two biggest drugmakers are still committed to new investments.
AstraZeneca is finishing a $500 million headquarters and research center in Cambridge, while GlaxoSmithKline pledged $360 million to expand manufacturing in the United Kingdom in July, just five weeks after the Brexit vote.
Novo Nordisk has built a booming business over the last two decades by focusing on diabetes, which is a growing problem worldwide, driven by obesity and sedentary lifestyles. More recently, however, it has struggled with squeezed prices in the key U.S. market.
It said James Johnson, currently a professor at the University of British Columbia, had been appointed head of the Novo Nordisk Research Centre Oxford. Johnson is an expert on pancreas biology, insulin action and diabetes.
(Editing by Ruth Pitchford)